Incidence and outcome of contrast-associated acute kidney injury assessed with Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) criteria in critically ill patients of medical and surgical intensive care units: a retrospective study

Table 4 Morbidity and mortality in ICU patients after contrast administration

	CA-AKI	CA-NAKI	OR	95% CI	P
	(n = 52)	(n = 283)	OR	95% CI	P
RRT after CM use	18(34.6%)	69(24.4%)	1.6	0.87-3.09	0.13
Diuretics after CM use	37(71.2%)	168(59.4%)			0.12
CM use after admission (days)	4[0–51]	4[0–80]			0.68
ICU discharge after CM use (days)	6.5[1–124]	7[1–285]			0.83
ICU LOS (days)	14[1.5-26.5]	15[6.5-23.5]			0.98
Hospital discharge after CM use (days)	29[1–262]	27[1–651]			0.69
ICU mortality	21(40.4%)	60(21.3%)	2.5	1.34-4.67	0.01
Hospital Mortality	28(53.8%)	101(35.7%)	2.1	1.16-3.82	0.02
Total mortality	29(55.8%)	108(38.2%)	2.0	1.12-3.71	0.02

Data are presented as N (%), median [minimum-maximum].
OR odds ratio, CI confidence interval, P probability value.
CA-AKI contrast-associated acute kidney injury, CA-NAKI contrast-associated no acute kidney injury, RRT renal replacement therapy, CM contrast medium, ICU intensive care unit, LOS length of stay.

ISSN: 1471-2253